Mounjaro is FDA-approved for type 2 diabetes, not weight loss on its own, so getting it prescribed almost always means qualifying through a diabetes diagnosis and supporting labs like HbA1c. If you don't have type 2 diabetes and want the same active drug for weight loss, the FDA-approved path is Zepbound, not Mounjaro, since both are tirzepatide under different brand names for different indications.
TL;DR
- How to get Mounjaro prescribed for weight loss usually means qualifying under its type 2 diabetes indication first.
- Without diabetes, tirzepatide is prescribed as Zepbound, the same molecule FDA-approved for chronic weight management.
- GoodLife Health's $299/month Cardiometabolic Optimization Membership includes a Biomarker Audit every 90 days to guide dosing decisions.
- SURMOUNT-1 trial data shows tirzepatide patients lost up to roughly 22.5% of body weight on average; individual results vary.
- Compounded tirzepatide is never part of GoodLife Health's prescribing protocol.
- Mounjaro's FDA approval covers type 2 diabetes only; weight loss alone points to Zepbound instead, even though it's the same drug.
- GoodLife Health treats prescribing as a labs-first decision: HbA1c, fasting glucose, and metabolic markers determine which prescription fits your diagnosis.
- Prescriptions are billed at pharmacy cost with zero markup and no dose-escalation fee, then reassessed every 90 days.
- Insurance formulary rules often require prior authorization and a documented diabetes ICD-10 code before covering Mounjaro.
- Compounded tirzepatide is not FDA-approved and is never part of GoodLife Health's prescribing model.
Why this matters
Most people searching for how to get Mounjaro prescribed for weight loss are actually asking the wrong question, and no telehealth quiz will tell them that upfront. Mounjaro's label covers type 2 diabetes. Zepbound, the same tirzepatide molecule dosed for weight management, is what most cash-pay patients without diabetes actually end up on.
That distinction matters because it changes what your clinician needs to see before writing anything. GoodLife Health treats this as a labs-first decision, not a checkbox form: your HbA1c, fasting glucose, and full metabolic picture determine which prescription actually fits your diagnosis, in 2026 and going forward. Skipping that step is how patients end up denied by insurance or stuck with a drug that isn't approved for their actual condition.
How to get Mounjaro prescribed for weight loss
The process runs through a licensed clinician, real labs, and a documented diagnosis, not a five-minute intake form. Here's the sequence GoodLife Health follows for every new patient:
- Complete a clinical evaluation. A board-certified physician reviews your weight history, current medications, and whether a direct primary care doctor can prescribe GLP-1 medications in your specific case.
- Get baseline labs drawn. HbA1c, a lipid panel, and metabolic markers establish whether you meet the diagnostic criteria for type 2 diabetes, or whether Zepbound is the more accurate fit.
- Clinician reviews results against FDA labeling. Mounjaro requires a documented type 2 diabetes diagnosis. Weight loss alone, without that diagnosis, points to Zepbound instead.
- Prescription is sent to the pharmacy. GoodLife Health bills the medication at pharmacy cost, with zero markup and no dose-escalation fee added as you titrate up.
- Dose titration is monitored. Your clinician adjusts dosing on a defined schedule and checks in on side effects, tolerance, and progress.
- Labs repeat on a 90-day cadence. The next Biomarker Audit reassesses HbA1c, lipids, and inflammation markers to confirm the plan is still working.
A prescription written before bloodwork isn't medicine, it's guesswork with a shipping label.
Mounjaro vs. Zepbound: same drug, different approval path
Both drugs are tirzepatide. The difference is the indication printed on the label, and that difference decides which one a clinician can legally prescribe for your situation.
Mounjaro vs. Zepbound
Same molecule, different approval path
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active molecule | Tirzepatide | Tirzepatide |
| FDA-approved use | Type 2 diabetes | Chronic weight management |
| Typical qualifying labs | HbA1c, fasting glucose | BMI, weight-related comorbidities, metabolic labs |
| Common payment path | Often insurance-covered for diabetes | Commonly cash-pay |
| Best for | Patients managing type 2 diabetes | Patients pursuing weight loss without a diabetes diagnosis |
Verdict: if your goal is weight loss and you don't have type 2 diabetes, Zepbound is the correct FDA-approved answer, not Mounjaro, even though the injection pen and the molecule are identical. Read the full breakdown in Mounjaro vs. Zepbound: same drug, different uses for how the two labels diverge.
Why Mounjaro approval criteria vary
Approval isn't arbitrary. A handful of factors determine whether a clinician can write Mounjaro specifically, versus routing you to Zepbound or another option:
- Diagnosis status — confirmed type 2 diabetes versus prediabetes or no diabetes at all.
- Baseline lab values — HbA1c and fasting glucose numbers that meet diagnostic thresholds.
- Insurance formulary rules — many plans require prior authorization and a documented diabetes ICD-10 code before covering Mounjaro.
- Weight-related comorbidities on file — sleep apnea, high blood pressure, or metabolic syndrome documented in your history.
- Whether you're switching from another GLP-1 — prior tirzepatide or semaglutide use changes the titration starting point.
- Clinician judgment based on your full history, not a one-time symptom checklist. Coverage questions specifically are covered in how to get tirzepatide covered by insurance.
One flat fee for the doctor. Zero markup on the medicine. That's the model GoodLife Health runs on regardless of which tirzepatide brand ends up on your prescription.
HbA1c, a full lipid panel, and fasting glucose are the baseline labs most clinicians order before starting tirzepatide, along with a broader metabolic and inflammation panel to rule out other drivers of weight gain. GoodLife Health folds these into its quarterly Biomarker Audit rather than a one-time snapshot.
Can I get Mounjaro without having diabetes?
Getting Mounjaro without a type 2 diabetes diagnosis is not the intended FDA pathway — the label specifically covers diabetes management, so a clinician prescribing for weight loss alone would typically write Zepbound instead, since it carries the weight-management indication for the same molecule.
What labs do I need before starting tirzepatide?
HbA1c, a full lipid panel, and fasting glucose are the baseline labs most clinicians order before starting tirzepatide, along with a broader metabolic and inflammation panel to rule out other drivers of weight gain. GoodLife Health folds these into its quarterly Biomarker Audit rather than a one-time snapshot.
How much weight can I lose on tirzepatide?
Tirzepatide patients lost up to roughly 22.5% of body weight on average in the SURMOUNT-1 trial, though individual results vary based on dose, adherence, and baseline metabolic health. That figure describes trial averages, not a guarantee for any single patient.
FAQ
How do I get Mounjaro prescribed for weight loss?
You get Mounjaro prescribed by completing a clinical evaluation and lab work that confirms a type 2 diabetes diagnosis, since that's the drug's FDA-approved indication. Without diabetes, a clinician typically prescribes Zepbound, the same tirzepatide molecule approved for chronic weight management.
Is Mounjaro the same as Zepbound?
Mounjaro and Zepbound contain the same active drug, tirzepatide, but carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved specifically for chronic weight management.
Can a telehealth doctor prescribe Mounjaro?
Yes, a licensed telehealth physician can prescribe Mounjaro after reviewing your labs and diagnosis, the same way an in-person doctor would. GoodLife Health's clinicians are board-certified and licensed in all 50 states as of 2026.
What labs are required before starting tirzepatide?
HbA1c, a lipid panel, and fasting glucose are the standard labs required before starting tirzepatide, plus a broader metabolic screen in most concierge models. These labs determine whether Mounjaro or Zepbound is the medically appropriate choice.
Does insurance cover Mounjaro for weight loss?
Insurance coverage for Mounjaro is built around its type 2 diabetes indication, so coverage for weight loss alone is inconsistent and often requires prior authorization. Cash-pay tirzepatide for weight management typically routes through Zepbound instead.
How long does it take to get approved for tirzepatide?
Approval timing depends on how quickly labs come back and how a clinician reviews them, which can take anywhere from a few days to a couple of weeks depending on the practice. A labs-first model means the prescription follows the results, not a fixed calendar date.
Is compounded tirzepatide the same as Mounjaro?
No, compounded tirzepatide is not FDA-approved and is not the same regulated product as branded Mounjaro or Zepbound. GoodLife Health prescribes branded, FDA-approved tirzepatide only, never a compounded version.
What happens if I don't have type 2 diabetes but want tirzepatide?
If you don't have type 2 diabetes, a clinician evaluating you for tirzepatide will typically prescribe Zepbound instead of Mounjaro, since Zepbound carries the FDA approval for weight management. The molecule is identical; the label and the qualifying diagnosis are what differ.
One last thing
The detail most patients miss: Mounjaro and Zepbound use the same injector, the same dose schedule, and the same titration curve. The only thing separating them is a diagnosis code and a label. If your HbA1c comes back one point under the diabetes threshold, you're not being denied a better drug, you're being routed to the correctly labeled version of the same one. That's not a technicality worth fighting; it's the FDA's approval structure working as intended, and it's why labs come before the prescription, not after.
Related guides
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/